PRIDE III Prison Interventions and HIV Prevention Collaboration
This study is looking at ways to improve the use of Opioid Agonist Therapy (OAT) in prisons and probation systems in Tajikistan, Kyrgyzstan, Moldova, and Georgia. OAT is a treatment that can help prevent HIV in people who use opioids. The study aims to understand what makes it hard to offer OAT more widely and to help these countries expand their OAT programs. Researchers will survey OAT providers and people on probation, and also observe and interview probation clients and staff. The main goal is to see how many people receive OAT over a period of up to four years. You might be able to join if you are 18 or older and are either an OAT provider in a prison setting or a person on probation who has reported injecting opioids.
- Study design
- This is an interventional study planning to enroll 300 participants. The study does not specify if it is randomized or blinded.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants receiving Opioid Agonist Therapy (OAT) will be measured at baseline and up to 4 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
PRIDE III Prison Interventions and HIV Prevention Collaboration
At a glance
Conditions
Where it's being run
5 sites across 5 statesStudy leadership
- Frederick L Altice, MD · PRINCIPAL_INVESTIGATOR · Yale University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Number of participants receiving opioid agonist therapy (OAT)baseline up to 4 years
Number of patients receiving opioid agonist therapy (OAT) per OAT site.